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An increase of cellular phosphocholine (PC) and total choline (tCho)-containing com-
pounds as well as alterations in lipids have been consistently observed in cancer cells 
and tissue. These metabolic changes are closely related to malignant transformation, 
invasion, and metastasis. The study of cancer cells in culture plays an important role 
in understanding mechanisms leading to altered choline (Cho) and lipid metabolism in 
cancer, as it provides a carefully controlled environment. However, a solid tumor is a 
complex system with a unique tumor microenvironment frequently containing hypoxic 
and acidic regions and areas of nutrient deprivation and necrosis. Cancer cell–stromal 
cell interactions and the extracellular matrix may also alter Cho and lipid metabolism. 
Human tumor xenograft models in mice are useful to mimic the growth of human can-
cers and provide insights into the influence of in vivo conditions on metabolism. Here, 
we have compared metabolites, obtained with high resolution 1H MRS of extracts from 
human breast and prostate cancer cells in a 2-dimensional (2D) monolayer culture and 
from solid tumor xenografts derived from these cells, as well as the protein expression 
of enzymes that regulate Cho and lipid metabolism. Our data demonstrate significant 
differences in Cho and lipid metabolism and protein expression patterns between human 
breast and prostate cancer cells in culture and in tumors derived from these cells. These 
data highlight the influence of the tumor microenvironment on Cho and lipid metabolism.
Keywords: choline metabolism, lipid metabolism, choline kinase, breast cancer, prostate cancer, cell culture, 
xenograft model
inTrODUcTiOn
A solid tumor is a complex system with a unique microenvironment that frequently contains areas 
of hypoxia, extracellular acidosis, and necrosis (1). Cancer cell–stromal/endothelial cell interactions 
and nutrient deprivation are some of the additional factors that influence metabolism in solid tumors 
Abbreviations: Cho, choline; Chk, choline kinase; GPC, glycerophosphocholine; ER, estrogen receptor; FASN, fatty acid 
synthase; MRS, magnetic resonance spectroscopy; PC, phosphocholine; PL, phospholipase; PR, progesterone receptor; PtdCho, 
phosphatidylcholine; PtdE, phosphatidylethanolamine; tCho, total choline; TMS, tetramethylsilane; TSP, 3-(trimethylsilyl)
propionic 2,2,3,3-d4 acid.
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(1–3). Although investigating cancer cell metabolism using cells 
in culture has the advantages of rapid use and lower costs, it is 
important to validate these results with tumor studies because 
of the complexities of solid tumor microenvironments that may 
alter metabolism and gene expression profiles compared to cells 
in culture. This is important in the development of biomarkers 
and in identifying targets for cancer treatment.
Cancer cells display aberrant choline (Cho) and lipid 
metabolism. Phosphatidylcholine (PtdCho), the most abundant 
phospholipid in eukaryotic cell membranes, contributes to 
proliferative growth and programed cell death (4). High levels 
of cellular phosphocholine (PC) and total choline-containing 
compounds [tCho: the sum of Cho, PC, and glycerophosphocho-
line (GPC)] have been consistently observed in cancer cells and 
tumor tissue and are closely related to malignant transformation, 
invasion, and metastasis (5–12).
Among the enzymes that regulate Cho metabolism, overex-
pression of choline kinase (Chk), the enzyme that catalyzes the 
phosphorylation of Cho to yield PC in the first step of PtdCho 
biosynthesis (Kennedy pathway) (13, 14), is a major cause of 
increased PC and tCho observed in cancers (8, 11, 15). The 
elevated tCho level detected by 1H magnetic resonance spectros-
copy (MRS) is being evaluated as a specific biomarker of prostate 
cancer, and high tCho is associated with aggressiveness in breast 
cancer (11, 16). Downregulation of Chk-α has been shown to 
significantly reduce proliferation in breast cancer cells (17, 18) 
and tumors (9). Enzymes that control the catabolism of PtdCho 
include phospholipase A (PLA), PLC, and PLD. These enzymes 
maintain PtdCho levels. Cytosolic phospholipase A2 (cPLA2α) 
has significantly different expression levels in basal-like and 
luminal-like breast cancer xenografts (19). PLD1 is upregulated 
in various human cancers, including breast (20, 21), uterine (22), 
and endometrial (23) cancers. An association between PLD1 and 
Chk-α expression with breast cancer malignancy was recently 
observed (21). Deregulated Cho phospholipid metabolism is 
emerging as a metabolic hallmark of oncogenesis and tumor 
progression.
Lipids function as energy storage molecules, structural com-
ponents of cell membranes, and signaling molecules involved 
in cell growth, inflammation, and immunity (24, 25). Increased 
lipid biosynthesis is a characteristic feature of cancer. Elevated 
de novo fatty acid synthesis is necessary for rapidly proliferating 
tumor cells to continually provide lipids, such as phospholipids, 
for membrane production. Proton spectroscopy of lipid-soluble 
cancer cell and tumor extracts detects signals from fatty acids, 
cholesterol, and phospholipids. Fatty acid synthase (FASN) is 
an important lipogenic enzyme required for fatty acid synthesis. 
FASN overexpression has been reported in several human can-
cers including breast, prostate, colon, and ovary and has been 
associated with poor prognosis (26–32).
Here, we obtained high resolution 1H MR spectra of extracts 
from cancer cells, and the corresponding tumor xenografts 
derived from these cells, to identify differences in Cho and lipid 
metabolism between cells and tumors. We selected two human 
prostate (DU-145 and PC-3) and two human breast (MCF-7 and 
MDA-MB-231) cancer cell lines with different aggressiveness for 
these studies. Expression of Chk-α, cPLA2, PLD1, and FASN was 
characterized in cells and tumors to understand the molecular 
mechanisms underlying the differences in Cho and lipid metabo-
lism observed between cells and tumors. Significant differences in 
Cho metabolites, especially PC and tCho, were observed between 
cells and tumors that were reflected in the differences in enzyme 
expression. These results underline the importance of the tumor 
microenvironment and conditions that exist in vivo, in modulat-
ing the Cho and lipid metabolism of cells in tumors, and provide 
new insights into the regulation of these metabolic pathways.
MaTerials anD MeThODs
cell culture
Two prostate and two breast cancer cell lines were used in this 
study. PC-3 and DU-145 prostate cancer cells are both androgen 
independent, but PC-3 is more invasive and metastatic than 
DU-145 prostate cancer cells (33). MDA-MB-231 is a triple 
negative metastatic human breast cancer cell line, and MCF-7 
is an estrogen receptor/progesterone receptor-positive poorly 
metastatic human breast cancer cell line (33). All cell lines were 
obtained from American Type Culture Collection (Manassas, 
VA, USA) and were maintained in a humidified atmosphere with 
5% CO2 in air, at 37°C. The cell lines were grown in RPMI-1640 
medium supplemented with 10% fetal bovine serum (Sigma-
Aldrich, St. Louis, MO, USA) and 100  units/ml penicillin and 
100  µg/ml streptomycin (Life Technologies Ltd., Grand Island, 
NY, USA).
generation of Tumor Xenografts
Approximately 2 × 106 cells in 50 µL Hanks’ balanced salt solu-
tion (Sigma-Aldrich, St. Louis, MO, USA) were inoculated in 
the mammary fat pad (breast cancer cells) or the flank (prostate 
cancer cells) of severe combined immunodeficient mice. For 
MCF-7 tumors, a 17 β-estradiol pellet (0.18 mg 90-day release 
pellet, Innovative Research of America, Sarasota, FL, USA) was 
implanted subcutaneously 2 days prior to cancer cell inoculation. 
Mice were fed with Teklad global 18% protein extruded rodent 
diet (Harlan, Madison, WI, USA) that includes 1,200 mg/kg of 
Cho, 0.9% total saturated fatty acids, and 4.7% of total unsatu-
rated fatty acids with minerals, amino acids, vitamins, and no 
cholesterol.
Dual-Phase extraction of cells and 
Tumors
Cells were cultured to about 80% confluence, and medium was 
changed 3 h prior to cell collection to avoid any lack of nutri-
tion. Adherent cells were collected by trypsinization and counted 
using a hemocytometer after staining dead cells with trypan blue. 
Approximately 4–5 ×  107 cells were harvested for cell extrac-
tion. Solid tumors were excised at volumes of ~200–500  mm3 
(~0.2–0.4 g) and immediately freeze-clamped in liquid N2. The 
time from cell inoculation to tumor excision was approximately 
50 days for DU-145, 30 days for PC-3, 40 days for MCF-7, and 
60 days for MDA-MB-231 tumors.
Both lipid- and water-soluble extract fractions were obtained 
using a dual-phase extraction method as described previously 
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(17). Briefly, pelleted cells were mixed with 4  mL of ice-cold 
methanol and vigorously vortexed. For tumor samples, ground 
tumors in liquid N2 were mixed with 4 mL of ice-cold methanol 
and homogenized. After keeping samples on ice for 15 min, 4 mL 
of chloroform were added, vortexed vigorously, and kept on ice 
for 10 min. Finally, 4 mL of water were added and shaken well. 
All operations were performed on ice, and samples were stored 
at 4°C overnight for phase separation and later centrifuged at 
15,000 g at 4°C for 30 min. The water/methanol phase containing 
water-soluble cellular metabolites such as Cho, PC, and GPC were 
treated with ~100 mg of chelex beads (Sigma-Aldrich, St. Louis, 
MO, USA) to remove any divalent cations. After removing the 
beads, methanol was evaporated using a rotary evaporator. The 
remaining water phase was lyophilized. The chloroform phase 
(lipid-soluble phase) was collected in the tube, and chloroform 
was evaporated using nitrogen gas. Both phases of the extracts 
were stored at −20°C until use.
Magnetic resonance spectroscopy
Water-soluble extracts from cells and tumors were resuspended 
in 0.6 mL of deuterated water (D2O) containing 2.4 × 10−7 mol of 
3-(trimethylsilyl)propionic 2,2,3,3-d4 acid (TSP; Sigma-Aldrich, 
St. Louis, MO, USA) as an internal standard for MR spectral 
analysis. Lipid-soluble extracts were resuspended in 0.4  mL 
of chloroform-D and 0.2  mL of methanol-D4 with 0.05  v/v% 
tetramethylsilane (TMS) (Cambridge Isotope Laboratories, Inc., 
Tewksbury, MA, USA) as an internal standard. Fully relaxed 1H 
MR spectra of water-soluble extracts and lipid-soluble extracts 
were acquired on a Bruker Avance 11.7 T spectrometer (Bruker 
BioSpin Corp., Billerica, MA, USA) with flip angle = 30°, sweep 
width = 10,000 Hz, repetition time = 11.2 s, block size = 32 K, 
and scans = 128. MR spectra were analyzed using Bruker XWIN-
NMR 3.5 software (Bruker BioSpin) as previously described (34). 
Signal integrals of –N+(CH3)3 resonances of PC at ~3.226 ppm, 
GPC at ~3.235 ppm, and free Cho at ~3.208 ppm in water-soluble 
extracts were determined and normalized to cell number and cell 
volume and compared to the TSP standard. To determine concen-
trations of cell samples, peak integration (Imet) from 1H spectra of 
PC, GPC, and Cho were compared to that of the internal standard 
TSP (ITSP) according to the equation:
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In these equations, [metabolitecell] represents the intracellular 
concentration of the metabolite of interest expressed as mole per 
liter (M), ATSP is the number of moles of TSP (2.4 × 10−7 mol) 
in the sample, H is the number of protons contributing to the 
signal, Ncell is the cell number, and Vcell is the cell volume. To 
determine the cell volume, cell size was determined by trypsiniz-
ing the cells and measuring the diameter (d) of 100 randomly 
selected cells using an optical microscope and calculated as 
[(4π/3)  ×  (d/2)3]. The cell volumes used for calculation are 
MDA-MB-231: 2,050 µm3, MCF-7: 3,128 µm3, PC-3: 3,120 µm3, 
and DU-145: 3,630 µm3 (7).
Tumor metabolite concentration [metabolitetumor] was calcu-
lated in mole per liter (M), Vtumor is the tumor volume in liter 
(assuming 1 g = 1 mL).
In lipid phase samples, chemical shifts were referenced to the 
internal standard TMS resonance at 0 ppm using published data 
(35–38). To determine the arbitrary unit (A.U.) of metabolites 
from lipid phase samples, signal integrals (Imet) of methyl groups 
assigned to C18 of cholesterol (C18) at ~0.7 ppm, methyl groups 
(–CH3) at ~0.9 ppm, methylene groups (–(CH2)n–) at ~1.3 ppm, 
and ethylene groups (–CH = CH–) at ~5.4 ppm in acyl chains of 
lipids, –CH2–N in phosphatidylethanolamine (PtdE) at ~3.1 ppm, 
the Cho group (–N+(CH3)3) primarily from PtdCho at ~3.2 ppm 
peaks were determined and compared to that of TMS (ITMS). A.U. 
values were standardized by cell number (Ncell) or tumor weight 



















Cells were grown in culture medium and scraped into RIPA 
buffer [50  mM Tris, pH 7.4, 150  mM NaCl, 1  mM EDTA, 1% 
Triton-100, 1% sodium deoxycholate, 1  mM phenylmethylsul-
fonyl fluoride, 0.1% SDS, and a protease inhibitor cocktail at 
1:200 dilution (Sigma-Aldrich, St. Louis, MO, USA)], and cell 
lysates were incubated on ice for 30 min. Protein samples from 
tumors were prepared after grinding freeze-clamped tumors in 
lipid N2 and sonicating in Hepes buffer with a protease inhibi-
tor cocktail. Cell and tumor lysates were spun down at 16,000 g 
(refrigerated centrifuge 5415 R, Eppendorf, Westbury, NY, USA) 
and 4°C twice. Protein concentrations were estimated using the 
Bio-Rad DC assay (Bio-Rad, Hercules, CA, USA). Equal amounts 
of total protein (40 or 50 µg) from cells or tumors were resolved 
on one-dimensional 7.5% SDS-PAGE gels and transferred to 
a nitrocellulose membrane (Bio-Rad). After blocking in 5% 
milk-TBST (TBS Tween), the membrane was separately probed 
with a custom-made polyclonal Chk-α antibody (Proteintech 
Group, Inc., Chicago, IL, USA) (17), cPLA2 antibody (Santa Cruz 
Biotechnology, Inc. Dallas, TX, USA), FASN antibody (Santa 
Cruz Biotechnology), and PLD1 antibody (Abcam, Cambridge, 
MA, USA). Anti-GAPDH antibody (Molecular Probes, Eugene, 
OR, USA) was used for equal loading assessment. Secondary 
antibodies were horseradish peroxidase conjugated anti-mouse 
or anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA). 
Reactions were recorded on Blue Bio film (Denville Scientific, 
Metuchen, NJ, USA) following use of Super Signal West Pico 
Substrate (Pierce Biotech, Rockford, IL, USA).
statistical analysis
Data were expressed as mean ± SD. The statistical significance was 
evaluated using a two-tailed unpaired Student’s t-test. P values of 
FigUre 1 | representative 1h Mr spectra obtained from water-soluble extracts of (a) Pc-3 cells (4 × 107 cells) and (B) Pc-3 tumor xenograft (0.4 g). 
Spectra were acquired on a Bruker Avance 11.7 T spectrometer with a 30° flip angle, 10,000 Hz sweep width, 11.2 s repetition time, 32 K block size, and 128 
scans. TSP, 3-(trimethylsilyl)propionic 2,2,3,3-d4 acid, an internal standard at 0 ppm; PC, phosphocholine; GPC, glycerophosphocholine; H2O, water signal.
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less than 0.05 were considered to be significant unless otherwise 
stated. Four or more samples were used for cell culture data and 
tumor data.
resUlTs
levels of cho Metabolites in  
Water-soluble extracts  
Determined by Mrs
Representative 1H MR spectra of water-soluble metabolites 
obtained from PC-3 cells and a tumor extract are shown in 
Figure  1. Expanded Cho metabolite regions of water-soluble 
cell and tumor extract spectra from DU-145, PC-3, MCF-7, and 
MDA-MB-231 cell lines are shown in Figure 2 to demonstrate the 
differences in the pattern of Cho metabolites between the cell and 
tumor pairs. Data averaged over four cell studies and six tumors 
showed a consistent decrease of PC in tumors compared to cells 
in all four cell lines (Figure 3A). The two most aggressive cell lines 
(PC-3 and MDA-MB-231) showed the strongest decline of PC 
in tumors compared to cells. GPC tended to increase in tumors 
compared to cells in PC-3 and MDA-MB-231 with the exception 
of DU-145 cells where there was a significant decrease in tumors. 
The several fold decrease of PC overshadowed the small increase 
of GPC in tumors compared to cells, resulting in a significant 
decrease of tCho in PC-3, and MDA-MB-231 tumors compared 
to the cells. In DU-145 tumors, the decrease of both PC and GPC 
resulted in a significant decrease of tCho in tumors compared to 
the cells.
The PC/GPC ratio was higher in cells than in tumors 
(Figure 3B), and the differences were larger in the more malig-
nant cell lines (PC-3 and MDA-MB-231) compared to the less 
malignant cell lines (DU-145 and MCF-7). Interestingly, the 
higher PC/GPC ratio observed in the more aggressive cell lines 
FigUre 2 | representative choline metabolite regions of 1h Mr spectra obtained from water-soluble extracts of DU-145, Pc-3, McF-7, and 
MDa-MB-231 cells and the corresponding tumor xenografts. Spectra are expanded to display signals from 3.20 to 3.25 ppm. Peak assignments are: free 
Cho at ~3.208 ppm, PC at ~3.226 ppm, and GPC at ~3.235 ppm.
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FigUre 3 | (a) PC, GPC, and total choline (tCho) (PC + GPC + Cho) levels, and (B) PC/GPC in water-soluble extracts obtained from 1H MR spectra of DU-145, 
PC-3, MCF-7, and MDA-MB-231 cells (gray bar) or the corresponding tumor xenografts (white bar). Average cell number used for water-soluble extracts are 
DU-145: 4.09 ± 1.00 × 107 (n = 7), PC-3: 3.85 ± 0.40 × 107 (n = 6), MCF-7: 4.84 ± 0.99 × 107 (n = 10), and MDA-MB-231: 4.55 ± 0.93 × 107 (n = 4). Average 
tumor weights in gram used for water-soluble extracts are DU-145: 0.31 ± 0.07 (n = 8), PC-3: 0.34 ± 0.08 (n = 7), MCF-7: 0.28 ± 0.09 (n = 11), and MDA-
MB-231: 0.31 ± 0.05 (n = 7). Data represent mean ± SD. **P < 0.01, *P < 0.05 between cells and tumors.
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(PC-3 and MDA-MB-231) compared to the less aggressive cell 
lines (DU-145 and MCF-7) was not observed in tumor extracts.
levels of lipid Metabolites in  
lipid-soluble extracts  
Determined by Mrs
1H MRS was used to compare lipid-soluble metabolites from cells 
and tumors. Representative 1H MR spectra from MCF-7 cells 
are shown in Figure 4. Data summarized over multiple cell and 
tumor samples are presented as A.U./cell from cells in culture 
(Figure 5A) and A.U./g from tumors (Figure 5B). Data from the 
methyl groups assigned to C18 of cholesterol (C18), the methyl 
groups (–CH3), the methylene groups (–(CH2)n–), and ethylene 
groups (–CH=CH–) in acyl chains of lipids, –CH2–N in PtdE, the 
Cho group (–N+(CH3)3) primarily from PtdCho are presented. To 
compare cells and tumors within the same cell lines, metabolite 
integrals were normalized to the –CH3 signal to obtain ratios 
of C18/–CH3, –(CH2)n–/–CH3, PtdE/–CH3, –N+(CH3)3/–CH3, 
–CH=CH–/–CH3. Additional analysis was performed to obtain 
FigUre 4 | representative 1h Mr spectra obtained from lipid-soluble extracts of (a) McF-7 cells and (B) McF-7 tumor xenograft. Spectra were 
acquired on a Bruker Avance 11.7 T spectrometer and are expanded to display signals from 0 to 5.5 ppm (except for 3.7–4.8 ppm). Lipid spectra were acquired 
with a 30° flip angle, 10,000 Hz sweep width, 11.2 s repetition time, 32 K block size, and 128 scans. Peak assignments are: TMS, tetramethylsilane (internal 
standard) at 0 ppm, methyl groups assigned to C18 of cholesterol (C18) at ~0.7 ppm, the methyl groups (–CH3) at ~0.9 ppm, methylene groups (–(CH2)n–) at 
~1.3 ppm, and ethylene groups (–CH=CH–) at ~5.4 ppm in acyl chains of lipids, –CH2–N in phosphatidylethanolamine at ~3.1 ppm, and the choline group 
(–N+(CH3)3) primarily from phosphatidylcholine at ~3.2 ppm.
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FigUre 5 | (a) Lipid metabolites in arbitrary unit (A.U.)/cell from 1H MR spectra obtained from lipid-soluble extracts of DU-145, PC-3, MCF-7, and MDA-MB-231 
cells. (B) Lipid metabolites in A.U./g from 1H MR spectra obtained from lipid-soluble extracts of DU-145, PC-3, MCF-7, and MDA-MB-231 xenograft models. (c) 
Ratios of lipid resonances from cells (gray bar) and solid tumors (white bar). 1: C18/–CH3, 2: phosphatidylethanolamine (PtdE)/–CH3, 3: –N+(CH3)3/–CH3, 4: 
–CH=CH–/–CH3, 5: –CH=CH–/–(CH2)n–, 6: –(CH2)n–/–CH3, 7: –N+(CH3)3/PtdE, 8: –(CH2)n–/C18, 9: –(CH2)n–/–N+(CH3)3. Average cell number used for lipid extracts 
are DU-145: 4.30 ± 0.96 × 107 (n = 6), PC-3: 3.85 ± 0.40 × 107 (n = 6), MCF-7: 5.07 ± 0.92 × 107 (n = 7), and MDA-MB-231: 4.55 ± 0.93 × 107 (n = 4). Average 
tumor weights in gram used for lipid extracts are DU-145: 0.33 ± 0.07 (n = 6), PC-3: 0.34 ± 0.08 (n = 7), MCF-7: 0.27 ± 0.09 (n = 9), and MDA-MB-231: 
0.30 ± 0.05 (n = 6). Data represent mean ± SD. **P < 0.01, *P < 0.05, +P < 0.06 between cells and tumors.
ratios of –CH=CH–/–(CH2)n–, –N+(CH3)3/PtdE, –(CH2)n–/C18, 
and –(CH2)n–/–N+(CH3)3 (Figure 5C).
The degree of lipid unsaturation estimated from –CH=CH–/–
CH3 or –CH=CH–/–(CH2)n– was significantly and consistently 
higher in tumors than in cells, in all the cell lines (Figure 5C). 
The ratio of –(CH2)n–/–CH3, which is related to the length of 
fatty acids, was significantly higher in PC-3 tumors than in cells. 
Ratios of PtdCho (–N+(CH3)3) to –CH3 were higher in cells than 
in tumors in the breast cancer cell lines. The –N+(CH3)3/PtdE 
ratios were higher in cells than in tumors in the prostate cancer 
cell lines and the MDA-MB-231 breast cancer cell line but not in 
MCF-7 cells. Ratios of –(CH2)n–/C18 and –(CH2)n–/–N+(CH3)3 
were higher in tumors than in cells from more malignant PC-3 
and MDA-MB-231 cell lines. C18/–CH3 and –(CH2)n–/C18 results 
showed DU-145 tumors had higher ratio of cholesterol in lipids. 
Both aggressive PC-3 and MDA-MB-231 cell lines showed similar 
lipid metabolite changes in cells and tumors.
levels of Protein That are related to cho 
Phospholipid Metabolism and lipid 
Metabolism
Immunoblot assays of Chk-α, cPLA2, PLD1, and FASN antibod-
ies are shown in Figure 6A. A consistently higher expression of 
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FigUre 6 | (a) Protein levels of Chk-α, cPLA2, PLD1, and fatty acid synthase (FASN) determined by immunoblot assays of DU-145, PC-3, MCF-7, and MDA-
MB-231 cells (marked C) and the tumor xenografts (marked T). (B) Protein levels of FASN in DU-145 and MDA-MB-231 cells (C) and the tumor xenografts (T) were 
obtained from a separate immunoblot assay with different exposure time. 50 µg (a) or 40 µg (B) of protein was loaded on a 10% reducing SDS-PAGE gel. GAPDH 
protein levels were used for equal loading assessment.
Chk-α was observed in cells compared to solid tumors that was 
most pronounced in MDA-MB-231 cells.
Higher expression of cPLA2 was observed in DU-145, 
MDA-MB-231, and MCF-7 tumors compared to the cor-
responding cells. Like Chk-α, PLD1 was higher in cells than in 
corresponding tumors with the exception of PC-3 cells.
Overall, levels of FASN were higher in cells than in tumors. 
The levels of FASN were higher in PC-3 and MCF-7 cells than in 
the corresponding tumors (Figure 6A). Since levels of FASN in 
DU-145 and MDA-MB-231 were lower than in the other prostate 
or breast cancer cell lines, these were not detectable on the same gel 
(Figure 6A). Therefore, samples from DU-145 and MDA-MB-231 
cells and tumors were loaded separately and run with different 
exposure time (Figure  6B). MDA-MB-231 had higher level of 
FASN protein in cells than in tumors, and DU-145 had slightly 
higher or comparable level of FASN in cells than in tumors.
DiscUssiOn
Here, for the first time, we have compared Cho and lipid metabo-
lites in cells maintained in 2-dimensional (2D) monolayer cell cul-
ture to the corresponding tumor xenografts and have performed 
molecular characterization of some of the major enzymes that 
regulate Cho and lipid metabolism in these cells and tumors. We 
observed significant differences in metabolite and enzyme expres-
sion patterns between cells and tumors confirming the importance 
of the tumor microenvironment in modulating metabolism. 
A compendium of factors including vascularization that control 
substrate delivery and hypoxia, acidic extracellular pH (pHe), and 
areas of cell death can influence the enzymes and the metabolites 
measured in high resolution spectra of tumor extracts.
One common difference to emerge across all the cells lines was 
a significant decrease of PC and tCho in tumors compared to cells 
that was consistent with the decrease of Chk-α observed in the 
tumors compared to the cells. This uniform difference across cell 
lines is surprising given the differences in vascularization (33), 
necrosis, hypoxia, and acidosis that have been observed in these 
tumor models and implicates the high cellular density in tumors, 
compared to cells in culture, as one mechanism underlying the 
difference. Additional mechanisms causing the decrease of PC, 
tCho, and Chk-α in tumors may be related to cancer cell-stromal 
cell and cancer cell-extracellular matrix (ECM) interactions that 
are intrinsic to tumor growth in vivo.
The second common difference that emerged from the com-
parison was a decrease of FASN in tumors compared to cells. 
Again the uniformity of this observation across the cell lines 
suggests that the reduction of FASN in tumors was cell density, 
stromal cell, or ECM related. Given that mechanical stress can 
create significant changes in cell function (39), it is possible that 
cancer cells growing within an ECM may demonstrate differences 
in enzyme expression and consequently metabolism. The uniform 
decrease of FASN observed in the tumors may also explain the 
higher unsaturated fatty acids observed in tumors compared to 
cells, in all the cell lines. Although endogenous and exogenous 
fatty acids are utilized similarly by MDA-MB-231 and MCF-7 cells 
in culture (40), mouse diet contains higher unsaturated fat (4.7%) 
than saturated fat (0.9%), which may also contribute to increased 
unsaturated fatty acids observed in tumors compared to cells.
Another interesting observation that emerged from these 
studies was that the high PC/GPC ratio associated with aggres-
sive breast and prostate cancer cells in culture (6, 41) was not 
replicated in tumors. This was primarily because of the significant 
decrease of PC in tumors compared to cells as well as an increase 
of GPC in tumors compared to cells. Acidic pHe that is frequently 
observed in tumors (42) has been shown to decrease PC and 
increase GPC in cells (43). Further characterization, in the future, 
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of GPC phosphodiesterase, the enzyme that converts GPC into 
Cho and glycerol-3-phosphate (44, 45) and lysophospholipase, 
the enzyme that converts lyso-PtdCho to GPC (15), may pro-
vide further insights into the differences in GPC between cells 
and tumors observed here. Increased cell density has also been 
observed to increase GPC levels (46). We have previously studied 
PC-3, DU-145, and MDA-MB-231 cells in a cell perfusion system 
where multilayered cells grow on 3D beads and have observed 
similar metabolic profiles as observed in 2D culture, especially 
in PC-3 (47) and MDA-MB-231 cells (48). Although we cannot 
rule out differences between 2D and 3D culture contributing to 
the metabolic differences, the differences observed here are more 
likely due to the tumor microenvironment including cancer cell-
stromal cell and ECM interactions.
With the exception of the PC-3 cell line, PLD1 was higher 
in cells compared to tumors, and cPLA2 was higher in tumors 
compared to cells. In our experience (33), PC-3 tumors are the 
least vascularized in the four models studied here. The absence 
of a difference in PLD1 and cPLA2 between the PC-3 cell line 
compared to the remaining three cell lines may be related to the 
poor vascularization in PC-3 tumors and the resultant reduction 
of paracrine signaling from vascular molecules.
Additional characterization, in future studies, of metabolites 
and cytokines in the tumor interstitial fluid, necrosis, pH, and 
oxygenation as well as an expanded characterization of the 
enzymes in Cho and lipid metabolism in culture and in tumors 
will provide further insights into the mechanisms underlying the 
differences between cells and tumors observed here. Investigation 
of metabolite differences between primary tumors and metastatic 
growth will also provide important insights. Such insights will 
provide further understanding of the functioning of tumors that 
is critical to developing biomarkers and treatment strategies 
targeting metabolism.
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